WEBULL

Pfizer (PFE): Assessing Valuation After Recent Share Price Dip and Growth Narrative Shift

Simply Wall St · 10/17/2025 13:40

Pfizer (PFE) stock recently moved slightly lower, with the share price closing at $24.23. Investors seem to be weighing Pfizer’s performance following modest revenue declines over the past year, while net income showed a minor increase.

See our latest analysis for Pfizer.

Looking beyond the latest dip, Pfizer’s momentum has lost steam over the past year, with a 1-year total shareholder return of -11.4% and a muted 30-day share price return. Combined with the year-to-date weakness, this signals investors remain cautious as the company navigates recent challenges and reassesses its long-term growth prospects.

If you’re tracking the pharma sector’s twists and turns, see what stands out among other major players with our dedicated screener: See the full list for free.

With shares trading below analyst targets and some value indicators in play, the key question emerges: is Pfizer now trading at a bargain for long-term investors, or is the market fully accounting for its growth trajectory ahead?

Most Popular Narrative: 16% Undervalued

Pfizer’s most widely followed narrative sets a fair value about 16% above its last close, forecasting new drivers ahead for the pharma heavyweight.

Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non-small cell lung cancer, advanced ADC portfolio, and pipeline vaccines), stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages.

Read the complete narrative.

What makes this narrative stand out? The entire valuation hinges on ambitious earnings growth and stepped-up margins, with surprising profit forecasts just a few years out. Curious about what concrete financial projections and market shifts support this premium pricing? Uncover the bold expectations fueling this price target.

Result: Fair Value of $28.86 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing regulatory actions and intensifying competition from new market entrants could undermine Pfizer’s long-term earnings outlook and challenge this growth narrative.

Find out about the key risks to this Pfizer narrative.

Build Your Own Pfizer Narrative

If you see the story unfolding differently, or want to dig into the numbers and draw your own conclusions, it’s simple to build your perspective in just a few minutes. Do it your way

A great starting point for your Pfizer research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Don’t let fresh investment opportunities slip through your fingers. Now is the time to move ahead of the crowd and sharpen your next stock pick.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.